Cartalax Vial Size — Dosage Options for Research | Real

Cartalax Vial Size — Dosage Options for Research | Real Peptides

A single miscalculation in Cartalax vial size selection has derailed more research protocols than contamination or storage errors combined. Researchers who order 5mg vials expecting multi-week studies find themselves reconstituting every 72 hours, while those who default to 20mg vials discover their injection volumes require insulin syringes with graduations finer than standard equipment provides. The difference between productive research and resource waste often comes down to matching vial size to study design before the first reconstitution.

We've supplied Cartalax peptide to hundreds of research institutions across metabolic and cellular aging studies. The pattern is consistent: vial size mismatch is the most common setup error, and it's almost always caught too late. After the first batch is already reconstituted and the dosing schedule is locked in.

What Cartalax vial size should researchers select for peptide studies?

Cartalax vial size typically ranges from 5mg, 10mg, to 20mg of lyophilised peptide per vial. Selection depends on study duration, daily or weekly dosing frequency, injection volume precision requirements, and reconstitution volume capacity. A 5mg vial reconstituted in 2mL bacteriostatic water yields 2.5mg/mL concentration, while a 20mg vial in the same volume provides 10mg/mL. The latter requires smaller injection volumes but demands higher measurement precision. Most short-term studies (1–2 weeks, daily dosing) perform best with 10mg vials to balance dosing accuracy and peptide stability post-reconstitution.

Most peptide guides stop at listing vial sizes without explaining why concentration math determines success or failure. Cartalax vial size isn't just about how much peptide you receive. It dictates reconstitution volume, injection precision, measurement error margins, and the practical window before peptide degradation becomes a variable in your results. This article covers how to calculate optimal Cartalax vial size for your protocol, how reconstitution volume interacts with concentration to determine dosing accuracy, and the specific errors that occur when researchers mismatch vial size to injection equipment or study duration.

Understanding Cartalax Vial Size and Peptide Concentration

Cartalax vial size refers to the total mass of lyophilised peptide contained in a sealed glass vial before reconstitution. The number. 5mg, 10mg, 20mg. Represents the active peptide weight, not the total powder volume visible in the vial. That white or off-white powder includes the peptide plus excipients like mannitol or glycine used during lyophilisation to preserve structure, but the stated Cartalax vial size reflects only the bioactive compound.

Concentration is what you create through reconstitution, and it's the variable that determines every dose calculation in your protocol. If you add 2mL of bacteriostatic water to a 10mg Cartalax vial, you've created a 5mg/mL solution. Add 5mL to the same 10mg vial, and concentration drops to 2mg/mL. The same vial size produces entirely different solutions depending on the reconstitution volume you select. Researchers who fail to calculate this step before ordering often discover their dosing math doesn't align with their syringe graduations. A 0.05mL injection might deliver the correct dose at one concentration but miss by 40% at another.

Peptide stability post-reconstitution imposes a time constraint that makes Cartalax vial size selection critical. Once mixed with bacteriostatic water, reconstituted Cartalax remains stable for approximately 28 days when refrigerated at 2–8°C. Beyond that window, peptide degradation accelerates and dose consistency becomes unreliable. A 20mg vial might seem cost-effective, but if your protocol requires only 1mg per week, you're discarding 75% of the peptide after four weeks because degradation has rendered it unusable. The right Cartalax vial size is the one that gets fully utilised within the stability window your storage conditions provide.

Measurement precision is the third variable that interacts directly with Cartalax vial size. Standard insulin syringes (0.3mL or 0.5mL capacity) have graduation marks every 0.01mL. At a concentration of 2mg/mL, each 0.01mL mark represents 0.02mg of peptide. Manageable precision for most dosing schedules. At 10mg/mL concentration, that same 0.01mL mark represents 0.1mg of peptide, and small measurement errors compound quickly. If your protocol requires 0.5mg doses and you're working at 10mg/mL concentration, you need to draw exactly 0.05mL. A single graduation mark off in either direction introduces a 20% dosing error. Researchers using higher concentrations often don't realise they've exceeded the practical precision their equipment can deliver until they review dose logs and notice unexplained variability.

Our experience across peptide research supply has shown this repeatedly: the teams that calculate concentration, injection volume, and equipment precision before selecting Cartalax vial size complete studies with fewer protocol adjustments and tighter data variance. The teams that order based on cost per milligram alone encounter mid-study reconstitution changes, dosing recalibrations, and unexplained outcome variability that originates entirely from vial size mismatch.

Calculating Optimal Cartalax Vial Size for Study Protocols

The optimal Cartalax vial size is the one that delivers your total required peptide mass within the 28-day post-reconstitution stability window, using a concentration that keeps injection volumes within your syringe's precision range. This calculation requires three inputs: total study duration, dosing frequency, and dose per administration.

Start with total peptide consumption. If your protocol calls for 0.5mg Cartalax daily for 14 days, total consumption is 7mg. Add 10–15% overage to account for syringe dead volume and measurement variance. 7mg becomes approximately 8mg. A 10mg Cartalax vial provides enough peptide to complete the study with buffer, while a 5mg vial would require mid-study reconstitution of a second vial, introducing a protocol break that some institutional review boards flag as a stability concern.

Next, calculate reconstitution volume and resulting concentration. A 10mg vial reconstituted in 2mL bacteriostatic water yields 5mg/mL. To deliver a 0.5mg dose at that concentration, you draw 0.1mL per injection. Well within the precision range of standard insulin syringes. If you instead reconstituted the same 10mg vial in 5mL, concentration drops to 2mg/mL, and the same 0.5mg dose requires drawing 0.25mL. That's a larger, easier-to-measure volume, but it also means you're using more reconstituted solution per dose, which shortens the number of doses you can extract before the vial is depleted.

Stability timeline is the third constraint. Reconstituted Cartalax remains potent for 28 days refrigerated. If your study duration exceeds 28 days, you'll need multiple vials regardless of Cartalax vial size. A 12-week study with daily 0.5mg dosing requires 42mg total. Two 20mg vials plus one 5mg vial, reconstituted in sequence so no vial sits in solution longer than four weeks. Researchers who reconstitute all peptide at study start introduce a degradation gradient: early doses come from fresh solution, late doses from peptide that's been in bacteriostatic water for two months. That's a confounding variable masquerading as an efficiency decision.

Practical dosing precision sets the final boundary. Injection volumes below 0.05mL (5 units on a U-100 insulin syringe) introduce measurement error that exceeds 10% even with careful technique. If your calculated injection volume falls below that threshold, your concentration is too high. Select a smaller Cartalax vial size or increase reconstitution volume to bring dose volume back into a measurable range. Conversely, injection volumes above 0.5mL start to cause injection site discomfort in some animal models and require split-site administration, adding protocol complexity. The sweet spot for most Cartalax research protocols is 0.08mL to 0.3mL per injection, which corresponds to concentrations between 1.7mg/mL and 6mg/mL for typical dose ranges.

We've guided research teams through this exact calculation hundreds of times. The protocols that succeed match Cartalax vial size to study design with mathematical precision. The ones that encounter mid-study adjustments almost always traced back to skipping this step and ordering based on price per milligram without running the concentration and volume math first.

Reconstitution Volume and Its Effect on Cartalax Dosing Accuracy

Reconstitution volume is the single most impactful variable you control after selecting Cartalax vial size. It determines solution concentration, which in turn dictates every injection volume, measurement precision requirement, and practical dose accuracy you'll achieve across the study. Most dosing errors in peptide research don't originate from contamination or improper storage. They originate from reconstitution volume that wasn't calculated to match syringe precision and dose requirements.

Bacteriostatic water is the standard reconstitution medium for Cartalax peptide. It contains 0.9% benzyl alcohol as a preservative, which inhibits bacterial growth in the multi-dose vial and extends usability to 28 days post-reconstitution when refrigerated at 2–8°C. The volume you add directly determines concentration: 1mL added to a 10mg Cartalax vial yields 10mg/mL, while 2mL added to the same vial yields 5mg/mL, and 5mL yields 2mg/mL. There is no "correct" reconstitution volume. Only volumes that do or don't align with your dosing math and syringe graduations.

Higher concentrations (achieved with smaller reconstitution volumes) reduce the injection volume needed per dose. A 1mg dose from a 10mg/mL solution requires drawing only 0.1mL. The same 1mg dose from a 2mg/mL solution requires 0.5mL. Five times the injection volume. Smaller injection volumes are faster to administer and reduce injection site irritation in sensitive models, but they demand finer measurement precision. A 0.01mL error at 10mg/mL concentration represents 0.1mg of peptide, while the same 0.01mL error at 2mg/mL represents only 0.02mg. The higher the concentration, the more a small measurement error translates into dosing variance.

Lower concentrations (achieved with larger reconstitution volumes) create more forgiving measurement conditions but consume vial capacity faster. If your Cartalax vial size is 10mg and you reconstitute with 10mL bacteriostatic water to achieve 1mg/mL concentration, each 1mg dose requires drawing 1mL. Meaning the entire vial provides only 10 doses. That same 10mg vial reconstituted in 2mL provides 5mg/mL concentration and approximately 40 doses at 0.25mL per 1.25mg dose, depending on syringe dead volume. Larger reconstitution volumes are excellent for improving measurement precision, but they can deplete the vial faster than the study timeline anticipates if dose frequency is high.

Vial capacity imposes a physical ceiling. Standard Cartalax vials hold 2–3mL of solution comfortably. You can reconstitute a 10mg vial with 5mL bacteriostatic water, but you'll need to use a larger vial format or accept that solution will reach near the vial neck, making draws more difficult. Most researchers find 2mL reconstitution volume optimal for 10mg Cartalax vial size, 1–1.5mL for 5mg vials, and 3–4mL for 20mg vials. These volumes keep solution concentration in the 3–7mg/mL range, which balances dosing precision and injection volume for typical research protocols.

Our supply work with research institutions has revealed a consistent pattern: teams that document reconstitution volume in their standard operating procedures and calculate resulting concentration before the first vial is opened experience fewer mid-study protocol amendments. Teams that reconstitute "by feel" or defer the math until after mixing encounter dose variance they attribute to peptide quality, when the actual source is measurement error introduced by poorly matched concentration and syringe precision. If you're using Cartalax Peptide from Real Peptides, the lyophilised powder stability allows flexibility in reconstitution timing. But once you add bacteriostatic water, the concentration you create is locked in, and every dose calculation flows from that initial choice.

Cartalax Vial Size: Format Comparison

Selecting Cartalax vial size without comparing how each format performs across study duration, dosing precision, and cost efficiency leads to mid-protocol adjustments that compromise data consistency. The table below maps the three standard Cartalax vial sizes against practical research variables.

| Vial Size | Recommended Reconstitution Volume | Resulting Concentration | Typical Injection Volume (1mg dose) | Study Duration Coverage (1mg daily) | Cost Efficiency (per mg) | Professional Assessment |
|—|—|—|—|—|—|
| 5mg | 1mL | 5mg/mL | 0.2mL | 5 days | Moderate. Best for pilot studies | Ideal for short-term dose-finding or single-week protocols; minimises waste but requires frequent reconstitution for extended studies |
| 10mg | 2mL | 5mg/mL | 0.2mL | 10 days | High. Best balance of precision and coverage | Optimal for 1–2 week studies with daily dosing; concentration sits in the precision sweet spot for standard insulin syringes |
| 20mg | 3mL | 6.67mg/mL | 0.15mL | 20 days | Highest. But only if fully utilised within stability window | Best for multi-week studies or higher-dose protocols; requires careful measurement due to higher concentration; waste risk if study concludes early |

This comparison assumes daily 1mg dosing and 28-day post-reconstitution stability. Protocols with higher or lower dose requirements shift the optimal Cartalax vial size accordingly. A 0.5mg daily dose protocol extends the coverage duration by half, making a 10mg vial sufficient for 20 days instead of 10. Conversely, a 2mg daily dose protocol consumes a 10mg vial in five days, making the 20mg format more efficient if study duration exceeds two weeks.

Researchers often default to the largest Cartalax vial size assuming cost savings, but peptide degradation beyond the 28-day stability window eliminates that advantage. A 20mg vial used across a 12-week study requires splitting into two reconstitutions. One at study start, one at week four. Effectively functioning as two separate 10mg vials. The cost per milligram savings disappear once you account for discarded solution from the first vial and the additional bacteriostatic water required for sequential reconstitution.

Key Takeaways

• Cartalax vial size ranges from 5mg to 20mg of lyophilised peptide per vial; the number represents active peptide mass, not total powder volume including excipients.
• Concentration is determined by reconstitution volume. A 10mg vial mixed with 2mL bacteriostatic water yields 5mg/mL, while the same vial in 5mL yields 2mg/mL, directly affecting injection volume and measurement precision.
• Reconstituted Cartalax remains stable for approximately 28 days when refrigerated at 2–8°C; peptide degradation accelerates beyond this window, making vial size selection critical to avoiding waste.
• Injection volumes below 0.05mL introduce measurement error exceeding 10%; optimal dosing precision occurs between 0.08mL and 0.3mL per injection, corresponding to concentrations of 1.7–6mg/mL.
• A 10mg Cartalax vial reconstituted in 2mL bacteriostatic water is optimal for most 1–2 week daily dosing protocols, balancing concentration precision, injection volume, and stability timeline.
• Larger Cartalax vial sizes (20mg) provide cost efficiency only if the entire peptide mass is consumed within the 28-day post-reconstitution window; otherwise, degradation negates the per-milligram savings.

What If: Cartalax Vial Size Scenarios

What If My Study Duration Exceeds the 28-Day Stability Window?

Reconstitute peptide in sequence rather than all at once. Order multiple smaller Cartalax vial sizes (e.g., three 10mg vials instead of one 20mg plus waste) and reconstitute each vial only when the prior vial is depleted or approaching 28 days in solution. This approach eliminates the degradation gradient that occurs when peptide sits in bacteriostatic water for two months, ensures each dose comes from fresh solution with consistent potency, and aligns with institutional protocols that flag stability concerns during IRB review.

What If My Calculated Injection Volume Is Too Small for Accurate Measurement?

Increase reconstitution volume to lower concentration and raise injection volume into a measurable range. If a 10mg Cartalax vial reconstituted in 1mL yields 10mg/mL concentration and your 0.5mg dose requires drawing only 0.05mL. At the lower limit of syringe precision. Reconstitute the same vial with 2mL instead. Concentration drops to 5mg/mL, and the same 0.5mg dose now requires 0.1mL, doubling measurement precision. Alternatively, if reconstitution volume is already maxed out for your vial size, select a smaller Cartalax vial size to achieve lower concentration without exceeding vial capacity.

What If I Need to Dose Multiple Subjects Daily and Want to Minimise Preparation Time?

Select a larger Cartalax vial size and higher concentration to reduce injection volume per subject. A 20mg vial reconstituted in 2mL yields 10mg/mL concentration, allowing 1mg doses to be drawn as 0.1mL per subject. Fast to measure and administer across multiple animals. This works well for studies with 10 or more subjects dosed daily, where cumulative preparation time becomes a constraint. However, ensure your syringe graduations support the required precision at higher concentration; if not, the time saved in preparation is lost to dosing errors and protocol deviations.

What If I Accidentally Reconstituted with the Wrong Volume?

Recalculate concentration immediately and adjust dose volume to deliver the correct peptide mass. If you intended to add 2mL bacteriostatic water to a 10mg Cartalax vial but accidentally added 3mL, concentration is now 3.33mg/mL instead of 5mg/mL. To deliver a planned 1mg dose, draw 0.3mL instead of 0.2mL. The peptide mass remains correct even though concentration changed. Document the concentration adjustment in your protocol notes to maintain traceability. If the incorrect volume makes injection volumes impractically large or small, discard the vial and reconstitute a new one using the correct volume. Attempting to "fix" concentration by adding or removing liquid introduces contamination risk and is not worth the cost savings.

The Critical Truth About Cartalax Vial Size

Here's the honest answer: Cartalax vial size is almost never the limiting factor in study success. But selecting it without running the math first almost always is. Researchers treat vial size as a purchasing decision when it's actually a dosing precision decision. The 20mg vial isn't "better" than the 10mg vial; it's appropriate for different study designs, timelines, and dose ranges. Ordering based on cost per milligram without calculating reconstitution concentration, injection volume, and stability windows is how protocols end up with mid-study amendments, unexplained variance in dose delivery, and data sets that can't be compared across time points because early doses came from fresh peptide and late doses came from solution sitting in bacteriostatic water for six weeks.

The research-grade peptide Thymalin and Epithalon Peptide face identical vial size selection constraints. The principle applies across every lyophilised peptide format. The teams that calculate vial size, reconstitution volume, and resulting concentration before placing an order complete studies with fewer protocol deviations. The teams that order first and calculate later attribute dosing variance to peptide quality, injection technique, or subject variability, when the actual source is concentration mismatch that was baked into the study design before the first injection.

If your protocol is still in the planning phase, the optimal Cartalax vial size is the one that delivers total required peptide mass within 28 days post-reconstitution, using a concentration that keeps injection volumes between 0.08mL and 0.3mL for your dose range. If you've already ordered and realise mid-protocol that your vial size doesn't align with dosing precision, adjust reconstitution volume on the next vial rather than continuing with a format that introduces measurement error into every dose. A protocol amendment filed at week two is far less disruptive than trying to explain dose variance at manuscript review.

Selecting the right Cartalax vial size isn't about guessing. It's about working backward from your dose requirements, syringe precision, and study timeline to identify which format keeps all three variables in alignment. That calculation takes five minutes with a calculator and prevents weeks of troubleshooting later.